Cover Image
市場調查報告書

Kolltan Pharmaceuticals, Inc.的產品平台分析

Kolltan Pharmaceuticals, Inc. - Product Pipeline Review - 2016

出版商 Global Markets Direct 商品編碼 321340
出版日期 內容資訊 英文 38 Pages
訂單完成後即時交付
價格
Back to Top
Kolltan Pharmaceuticals, Inc.的產品平台分析 Kolltan Pharmaceuticals, Inc. - Product Pipeline Review - 2016
出版日期: 2016年02月29日 內容資訊: 英文 38 Pages
簡介

Kolltan Pharmaceuticals, Inc.是總公司設置於美國的製藥企業,正在開發以受體型蛋白酪氨酸激酶為標的單株抗體製劑。同時開發補足並強化癌症既有治療藥的藥劑,該公司的藥物候補KTN3379,正處於第一代抗腫瘤活性及藥物動力學的實驗中。

本報告提供Kolltan Pharmaceuticals, Inc. 的治療藥開發平台現狀及各開發階段比較分析,提供您藥物標的,作用機制,給藥途徑,各分子類型的治療藥評估,最新的企業新聞和發表,後期階段及中止的計劃等相關資訊。

目錄

Kolltan Pharmaceuticals, Inc. 的基本資料

  • Kolltan Pharmaceuticals, Inc. 概要
  • 主要資訊
  • 企業資料

Kolltan Pharmaceuticals, Inc. :R&D概要

  • 主要的治療範圍

Kolltan Pharmaceuticals, Inc. :開發平台評估

  • 各開發階段的開發中產品
  • 單劑產品

Kolltan Pharmaceuticals, Inc. :開發中產品概況

  • 臨床階段的開發中產品
    • 第一階段的產品/聯合治療模式
  • 初期階段的開發中產品
    • 前臨床階段的產品/聯合治療模式
    • 藥物研發階段的產品/聯合治療模式
  • ■Kolltan Pharmaceuticals, Inc. :藥物簡介
  • KTN-3379
  • KIT-ADC
  • KTN-0158
  • Monoclonal Antibody to Inhibit ALK for Cancer
  • Monoclonal Antibody to Inhibit c-MET for Cancer
  • Monoclonal Antibody to Inhibit DDR for Cancer and Osteoporosis
  • Monoclonal Antibody to Inhibit FGFR4 for Cancer
  • Monoclonal Antibody to Inhibit MERTK for Cancer, Inflammation and Infection
  • Monoclonal Antibody to Inhibit RON for Cancer

Kolltan Pharmaceuticals, Inc. :開發平台分析

  • 標的別
  • 各給藥途徑
  • 各分子類型
  • 各作用機制

Kolltan Pharmaceuticals, Inc. :最新的開發平台資訊

Kolltan Pharmaceuticals, Inc. :總公司和子公司的所在地

  • 總公司
  • 分公司及子公司

附錄

圖表一覽

本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

目錄
Product Code: GMDHC07974CDB

Summary

Global Markets Direct's, 'Kolltan Pharmaceuticals, Inc. - Product Pipeline Review - 2016', provides an overview of the Kolltan Pharmaceuticals, Inc.'s pharmaceutical research and development focus.

The report provides comprehensive information on the therapeutics under development by Kolltan Pharmaceuticals, Inc., complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and the dormant and discontinued projects.

Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data.

Scope

  • The report provides a snapshot of the pipeline therapeutic landscape of Kolltan Pharmaceuticals, Inc.
  • The report provides overview of Kolltan Pharmaceuticals, Inc. including its business description, key facts, and locations and subsidiaries
  • The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities
  • The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages
  • The report assesses Kolltan Pharmaceuticals, Inc.'s pipeline therapeutics based on drug target, mechanism of action (MoA), route of administration (RoA) and molecule type
  • The report features Kolltan Pharmaceuticals, Inc.'s out-licensed and partnered product portfolio and summarizes its dormant and discontinued projects

Reasons to buy

  • Evaluate Kolltan Pharmaceuticals, Inc.'s strategic position with total access to detailed information on its product pipeline
  • Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies
  • Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
  • Identify and understand important and diverse types of therapeutics under development for Kolltan Pharmaceuticals, Inc.
  • Identify potential new clients or partners in the target demographic
  • Plan mergers and acquisitions effectively by identifying key players and it's most promising pipeline therapeutics
  • Devise corrective measures for pipeline projects by understanding Kolltan Pharmaceuticals, Inc.'s pipeline depth and focus of pipeline therapeutics
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope

Table of Contents

  • Table of Contents
    • List of Tables
    • List of Figures
  • Kolltan Pharmaceuticals, Inc. Snapshot
    • Kolltan Pharmaceuticals, Inc. Overview
    • Key Information
    • Key Facts
  • Kolltan Pharmaceuticals, Inc. - Research and Development Overview
    • Key Therapeutic Areas
  • Kolltan Pharmaceuticals, Inc. - Pipeline Review
    • Pipeline Products by Stage of Development
    • Pipeline Products - Monotherapy
  • Kolltan Pharmaceuticals, Inc. - Pipeline Products Glance
    • Kolltan Pharmaceuticals, Inc. - Clinical Stage Pipeline Products
      • Phase I Products/Combination Treatment Modalities
    • Kolltan Pharmaceuticals, Inc. - Early Stage Pipeline Products
      • Preclinical Products/Combination Treatment Modalities
      • Discovery Products/Combination Treatment Modalities
  • Kolltan Pharmaceuticals, Inc. - Drug Profiles
    • KTN-0158
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • KTN-3379
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • KIT-SG3227
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • KTN-0182A
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • Monoclonal Antibody Conjugate to Antagonize ALK Receptor for Oncology
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • Monoclonal Antibody Conjugate to Inhibit Axl for Cancer, Inflammation and Infection
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • Monoclonal Antibody Conjugate to Target ErbB-3 for Oncology
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • Monoclonal Antibody to Inhibit c-MET for Cancer
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • Monoclonal Antibody to Inhibit DDR for Cancer and Osteoporosis
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • Monoclonal Antibody to Inhibit FGFR4 for Cancer
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • Monoclonal Antibody to Inhibit MERTK for Cancer, Inflammation and Infection
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • Monoclonal Antibody to Inhibit RON for Cancer
      • Product Description
      • Mechanism of Action
      • R&D Progress
  • Kolltan Pharmaceuticals, Inc. - Pipeline Analysis
    • Kolltan Pharmaceuticals, Inc. - Pipeline Products by Target
    • Kolltan Pharmaceuticals, Inc. - Pipeline Products by Route of Administration
    • Kolltan Pharmaceuticals, Inc. - Pipeline Products by Molecule Type
    • Kolltan Pharmaceuticals, Inc. - Pipeline Products by Mechanism of Action
  • Kolltan Pharmaceuticals, Inc. - Recent Pipeline Updates
  • Kolltan Pharmaceuticals, Inc. - Locations And Subsidiaries
    • Head Office
    • Other Locations & Subsidiaries
  • Appendix
    • Methodology
    • Coverage
    • Secondary Research
    • Primary Research
    • Expert Panel Validation
    • Contact Us
    • Disclaimer

List of Tables

  • Kolltan Pharmaceuticals, Inc., Key Information
  • Kolltan Pharmaceuticals, Inc., Key Facts
  • Kolltan Pharmaceuticals, Inc. - Pipeline by Indication, 2016
  • Kolltan Pharmaceuticals, Inc. - Pipeline by Stage of Development, 2016
  • Kolltan Pharmaceuticals, Inc. - Monotherapy Products in Pipeline, 2016
  • Kolltan Pharmaceuticals, Inc. - Phase I, 2016
  • Kolltan Pharmaceuticals, Inc. - Preclinical, 2016
  • Kolltan Pharmaceuticals, Inc. - Discovery, 2016
  • Kolltan Pharmaceuticals, Inc. - Pipeline by Target, 2016
  • Kolltan Pharmaceuticals, Inc. - Pipeline by Route of Administration, 2016
  • Kolltan Pharmaceuticals, Inc. - Pipeline by Molecule Type, 2016
  • Kolltan Pharmaceuticals, Inc. - Pipeline Products by Mechanism of Action, 2016
  • Kolltan Pharmaceuticals, Inc. - Recent Pipeline Updates, 2016
  • Kolltan Pharmaceuticals, Inc., Subsidiaries

List of Figures

  • Kolltan Pharmaceuticals, Inc. - Pipeline by Top 10 Indication, 2016
  • Kolltan Pharmaceuticals, Inc. - Pipeline by Stage of Development, 2016
  • Kolltan Pharmaceuticals, Inc. - Monotherapy Products in Pipeline, 2016
  • Kolltan Pharmaceuticals, Inc. - Pipeline by Target, 2016
  • Kolltan Pharmaceuticals, Inc. - Pipeline by Molecule Type, 2016
  • Kolltan Pharmaceuticals, Inc. - Pipeline Products by Mechanism of Action, 2016
Back to Top